- Report
- January 2026
- 239 Pages
Global
From €5237EUR$5,966USD£4,350GBP
- Report
- September 2026
- 257 Pages
Global
From €5316EUR$5,850USD£4,569GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- January 2026
- 185 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- July 2026
- 400 Pages
Global
From €7260EUR$7,990USD£6,241GBP
- Report
- January 2026
- 120 Pages
Global
From €4316EUR$4,750USD£3,710GBP
- Report
- July 2026
- 160 Pages
Global
From €3017EUR$3,320USD£2,593GBP
€3771EUR$4,150USD£3,242GBP
- Report
- October 2025
- 89 Pages
United States
From €4089EUR$4,500USD£3,515GBP
- Report
- September 2026
- 196 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 181 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 198 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- April 2026
- 91 Pages
Global
From €3500EUR$4,126USD£3,114GBP
- Report
- September 2026
- 182 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 197 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 192 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 199 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 180 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 180 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 189 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 187 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP

The Rheumatoid Arthritis Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat rheumatoid arthritis, an autoimmune disorder that causes inflammation of the joints. These drugs are used to reduce inflammation, pain, and stiffness, as well as to prevent joint damage. They can be divided into two categories: disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (BRMs). DMARDs are used to slow the progression of the disease, while BRMs are used to reduce inflammation and pain.
The Rheumatoid Arthritis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more